JOURNAL COURIERBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL & COURIER
Company Title:
Company Description:
Keywords to Search:
Company Address:	5853 Liberty Creek Drive North,GREENFIELD,IN,USA
ZIP Code: Postal Code:	47901-1448
Telephone Number:	6163748883 (+1-616-374-8883)
Fax Number:	6163740071 (+1-616-374-0071)
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	731304
USA SIC Description:	Media Brokers
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
MAGGIE JOHNSON
JOE ROBERTS
HOOSIERHOMESREALTY

Next company profile:
MICHAEL ROCHFORD
MOONLIGHT ENTERPRISES
FRAME DESIGN BY JULIAN

Company News:

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual Current disease-modifying therapies for multiple sclero
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung . . .
Neoadjuvant nivolumab plus chemotherapy significantly improved pathological complete response and event-free survival in patients with resectable non–small-cell lung cancer (NSCLC) in a phase 3
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Background Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited